Preclinical Demonstration of a Novel Treatment with High Efficacy and No Detectable Toxicity for Inflammatory Skin Conditions including Psoriasis.

Vanden Heuvel, John P; Zhou, Shuling; Patel, Anisha B; Kamerow, Harry N; Baran, Peter; Ford, John P

Vanden Heuvel, John P; Zhou, Shuling; Patel, Anisha B; Kamerow, Harry N; Baran, Peter; Ford, John P.

Afiliación

Vanden Heuvel JP; Department of Veterinary and Biomedical Sciences, Penn State University, University Park, PA 16802, USA.
Zhou S; Asymmetric Therapeutics LLC, 141 Main St., P.O. Box J, Unadilla, NY 13849, USA.
Patel AB; Indigo Biosciences, Inc., 3006 Research Drive, State College, PA 16801, USA.
Kamerow HN; Department of Veterinary and Biomedical Sciences, Penn State University, University Park, PA 16802, USA.
Baran P; Asymmetric Therapeutics LLC, 141 Main St., P.O. Box J, Unadilla, NY 13849, USA.
Ford JP; Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Biomed Res Int ; 2023: 4878774, 2023.

Article en En | MEDLINE | ID: mdl-37469991

Asunto(s)

Psoriasis; Humanos; Psoriasis/metabolismo; Piel/patología; Queratinocitos/metabolismo; Factor de Necrosis Tumoral alfa/metabolismo; Metotrexato/farmacología; Metotrexato/uso terapéutico; Proliferación Celular

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Biomed Res Int Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google